These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38971872)

  • 1. An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses.
    Zhang W; Zeng Y; Xiao Q; Wu Y; Liu J; Wang H; Luo Y; Zhan J; Liao N; Cai Y
    Nat Commun; 2024 Jul; 15(1):5670. PubMed ID: 38971872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 3. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.
    Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZBTB28 inhibits breast cancer by activating IFNAR and dual blocking CD24 and CD47 to enhance macrophages phagocytosis.
    Li L; Gong Y; Tang J; Yan C; Li L; Peng W; Cheng Z; Yu R; Xiang Q; Deng C; Mu J; Xia J; Luo X; Wu Y; Xiang T
    Cell Mol Life Sci; 2022 Jan; 79(2):83. PubMed ID: 35048182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting tumor cell-to-macrophage communication by blocking Vtn-C1qbp interaction inhibits tumor progression via enhancing macrophage phagocytosis.
    Zhang C; Liu Y; Jiang J; Chen C; Duan Z; Su H; Wang S; Tian B; Shi Y; Xiang R; Luo Y
    Theranostics; 2024; 14(7):2757-2776. PubMed ID: 38773982
    [No Abstract]   [Full Text] [Related]  

  • 7. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
    Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL
    Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity.
    de Silva S; Fromm G; Shuptrine CW; Johannes K; Patel A; Yoo KJ; Huang K; Schreiber TH
    Cancer Immunol Res; 2020 Feb; 8(2):230-245. PubMed ID: 31852716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
    Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
    MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinatorial macrophage induced innate immunotherapy against Ewing sarcoma: Turning "Two Keys" simultaneously.
    Luo W; Hoang H; Miller KE; Zhu H; Xu S; Mo X; Garfinkle EAR; Costello H; Wijeratne S; Chemnitz W; Gandhi R; Liao Y; Ayello J; Gardenswartz A; Rosenblum JM; Cassady KA; Mardis ER; Lee DA; Cripe TP; Cairo MS
    J Exp Clin Cancer Res; 2024 Jul; 43(1):193. PubMed ID: 38992659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy.
    Jin S; Wang H; Li Y; Yang J; Li B; Shi P; Zhang X; Zhou X; Zhou X; Niu X; Wu M; Wu Y; Zhai W; Qi Y; Gao Y; Zhao W
    Cell Commun Signal; 2024 Mar; 22(1):173. PubMed ID: 38462636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoration of miR-340 controls pancreatic cancer cell
    Xi Q; Zhang J; Yang G; Zhang L; Chen Y; Wang C; Zhang Z; Guo X; Zhao J; Xue Z; Li Y; Zhang Q; Da Y; Liu L; Yao Z; Zhang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.
    Ozawa Y; Harutani Y; Oyanagi J; Akamatsu H; Murakami E; Shibaki R; Hayata A; Sugimoto T; Tanaka M; Takakura T; Furuta K; Okuda Y; Sato K; Teraoka S; Ueda H; Tokudome N; Kitamura Y; Fukuoka J; Nakanishi M; Koh Y; Yamamoto N
    Cancer Sci; 2021 Jan; 112(1):72-80. PubMed ID: 33084148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
    Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment.
    Wang R; Zhang C; Cao Y; Wang J; Jiao S; Zhang J; Wang M; Tang P; Ouyang Z; Liang W; Mao Y; Wang A; Li G; Zhang J; Wang M; Wang S; Gui X
    Theranostics; 2023; 13(1):148-160. PubMed ID: 36593962
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapeutic Blockade of CD47 Inhibitory Signaling Enhances Innate and Adaptive Immune Responses to Viral Infection.
    Cham LB; Torrez Dulgeroff LB; Tal MC; Adomati T; Li F; Bhat H; Huang A; Lang PA; Moreno ME; Rivera JM; Galkina SA; Kosikova G; Stoddart CA; McCune JM; Myers LM; Weissman IL; Lang KS; Hasenkrug KJ
    Cell Rep; 2020 Apr; 31(2):107494. PubMed ID: 32294445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
    Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
    J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.
    Ni H; Cao L; Wu Z; Wang L; Zhou S; Guo X; Gao Y; Jing H; Wu M; Liu Y; Ding J; Zhang P; Zhou Y; Chen B; Xiong Y; Sun J; Prinz B; Baruah H; Geoghegan J; Yu M; Wu W; Liu J
    Cancer Immunol Immunother; 2022 Feb; 71(2):353-363. PubMed ID: 34165607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.